Navigation Links
VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis
Date:10/7/2010

SAN DIEGO and SEATTLE, Oct. 7 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today results from its randomized, placebo controlled clinical trial evaluating VTX-1463 for the treatment of allergic rhinitis. The results demonstrated that VTX-1463 significantly improved allergy symptoms based on Total Nasal Symptom Scores (TNSS) compared to placebo (p=0.012). TNSS is the standard endpoint used in allergy trials that takes into account nasal congestion, itching, sneezing and rhinorrhea. VTX-1463 is a selective TLR8 agonist that is delivered intranasally on a weekly basis.

"It's encouraging to see such robust results from this new selective TLR8 agonist," said Friedrich Horak, M.D., Professor of the Medical University Vienna and Vienna Challenge Chamber (VCC) in Vienna, Austria, and principal investigator of this study. "Given that allergic rhinitis impacts a substantial portion of the overall population, a potential drug like VTX-1463 that is administered intranasally once a week could provide an important advantage for patients."

The clinical trial assessed safety and efficacy of VTX-1463 in a randomized, placebo controlled study in 80 patients with confirmed allergy to grass pollen in the Vienna Challenge Chamber. VTX-1463 was evaluated as a stand-alone agent administered once-weekly in four doses intranasally. Further details of the trial and results will be presented at an upcoming scientific meeting.

"These data provide clinical proof-of-concept for further development of VTX-1463 in allergic rhinitis as well as the rationale to potentially explore other allergic indications," said Robert Hershberg, M.D., Ph.D., Co-founder and Chief Medical Officer at VentiRx. "The VTX-1463 data combined with recent data generated with VTX-2337 in oncology validates TLR8 as an imp
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
2. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
3. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
4. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
7. MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Savient Pharmaceuticals Announces Dismissal of Class Action Lawsuit
9. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
10. Transcept Pharmaceuticals to Present at BIO Investor Forum
11. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MINNEAPOLIS, Jan. 19, 2012 Zyga Technology, Inc. announced ... the company and will serve as Vice President of ... (Logo: http://photos.prnewswire.com/prnh/20110118/CG30384LOGO ) Joe ... Medical Device Industry.  He began his career at Codman ...
... Berkery Noyes, an independent middle market investment bank, today ... trend report for the Pharma & Healthcare ... report analyzes the sector for 2011 and compares it ... includes information and technology companies servicing pharmaceutical, healthcare payer, ...
Cached Medicine Technology:Zyga Technology, Inc. Makes Two Key Additions to the Sales Leadership Team 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 2Berkery Noyes Releases 2011 Pharma & Healthcare Information and Technology Industry Mergers & Acquisitions Report 3
(Date:7/25/2014)... The new report “Carbohydrase Market by Applications (Food ... Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, ... Forecasts to 2019", by MarketsandMarkets, identifies the driving ... with analysis of trends, opportunities, winning imperatives, and ... forecasted on the basis of major regions such ...
(Date:7/25/2014)... In today’s technological era, every organization is dependable on ... the organization in various ways. But there is high ... the confidential information and processes of the organization. ... and protect the enterprise from various types of threats ... to the comp may. The equipment's of the EGRC ...
(Date:7/25/2014)... 25, 2014 The Rottenstein Law ... with over 25 years of experience advocating for ... prescription drugs, announces the launch of its new ... those who believe they have been harmed by ... offers valuable information about the severe adverse side ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines and segments ... of revenue. The liquid chromatography reagents market in Europe ... is estimated to grow to around $1581.8 million by ... to 2018. , Browse through the TOC of the ... of the in-depth analysis provided. This also provides a ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Unlike children, the vast majority ... their plate at mealtime, according to a new study. ... world -- not just Americans, researchers from Cornell University revealed. ... lose weight or improve their eating habits make better choices. ... into your stomach," researcher Brian Wansink, director of the ...
Breaking Medicine News(10 mins):Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Most Adults Are Members of 'Clean Plate Club' 2
... belief that adolescent boys tend to take romance for a ... to heart matters, they might not be so fleeting after ... outside, an adolescent boy fails to communicate his emotions, leading ... ,Boys are more vulnerable and emotionally engaged in romantic ...
... at the University of California, appearing in the latest ... says that people// with autism never "daydream" The researchers ... of people having autism and those not affected by ... the brain, emotions and thoughts are processed. However this ...
... India Institute of Medical Sciences (AIIMS) here is running short ... than sanctioned//, Rajya Sabha was informed Friday. ,Replying to ... Panabaka Lakshmi said that the AIIMS was running with just ... ,She also informed the house that during 2003-05, ...
... Economy Research Institute at the University of Massachusetts listed ... air pollution//. This list is officially called the Toxic ... source of air pollution. This is based on air ... the United States. , The various factors ...
... in Australia's medical schools have become so inadequate that ... parts even confusing// certain vital organs with each other. ... have raised concerns that medical students are not being ... the students are not properly trained in anatomy. According ...
... of Medical Sciences (RIMS) is organising a three-day intensive ... states from today// the 11th April. This course is ... the shortfall of sports medicine specialists in the Northeast; ... ,Professor L Fimate the RIMS director, while addressing ...
Cached Medicine News:Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3
The Shandon Citadel is a low cost, reliable, time-tested carousel-type tissue processor with convenient touch key operation. The Citadel 2000 has 110 cassette capacity and the Citadel 1000 has a cap...
... Senior Grossing Wokrstation is a durable, ... for gross examination and sectioning of ... 3 efficient ventilation systems and options ... water faucets, table rinses, disposals and ...
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... Gross-Star Grossing Workbench is a durable, ... gross examination and sectioning of specimens. ... ventilation with a choice of 3 ... for cold/hot water faucet, optional formalin ...
Medicine Products: